Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Up 48.8% in March

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 142,800 shares, a growth of 48.8% from the February 28th total of 96,000 shares. Approximately 3.1% of the shares of the company are short sold. Based on an average daily trading volume, of 222,800 shares, the short-interest ratio is presently 0.6 days.

Entero Therapeutics Price Performance

Shares of ENTO opened at $0.48 on Tuesday. Entero Therapeutics has a fifty-two week low of $0.19 and a fifty-two week high of $3.16. The business has a 50-day moving average of $0.52 and a 200 day moving average of $0.53.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.